Literature DB >> 7931173

Correlation of proteolytic cleavage of F protein precursors in paramyxoviruses with expression of the fur, PACE4 and PC6 genes in mammalian cells.

T Sakaguchi1, Y Fujii, K Kiyotani, T Yoshida.   

Abstract

The fusion (F) protein precursor of virulent Newcastle disease virus (NDV) strains and human parainfluenza virus type 3 (HPIV3) has a multibasic amino acid sequence at the cleavage site, and intracellular cleavage activation occurs in a variety of cells. The host protease responsible for the cleavage has been proposed to be a subtilisin-like protease (subtilase) such as furin (the product of the fur gene). We found that the lymphocyte cell lines MOLT-4, Ramos and Daudi, in addition to NALM6, lacked the ability to fully cleave the F protein precursor of virulent NDV. In contrast, MT4 as well as the non-lymphocyte cell lines HeLa and Hep2 cleaved the F protein precursor efficiently. To investigate the role of subtilases in proteolytic processing, we examined the gene expression of candidate subtilases, furin, PACE4 and PC6 in these cleavage-competent and -incompetent cells. Considerable expression of the fur gene was observed in the cleavage-competent cells, but little or no expression was detected in the cleavage-incompetent cells. PACE4 and PC6 gene expression was observed in some of the cleavage-competent cells but not in the cleavage-incompetent cells. These results suggest that furin is the protease responsible for cleavage activation of the F protein of virulent NDV strains in cultured mammalian cells and the possibility is raised that PACE4 and PC6 also participate in processing in some of the cells. On the other hand, the HPIV3 F protein was cleaved efficiently in lymphocyte cells deficient in subtilases, suggesting that an unknown protease other than furin, PACE4 or PC6 may be involved in the processing.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7931173     DOI: 10.1099/0022-1317-75-10-2821

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  8 in total

1.  Isolation of the human PC6 gene encoding the putative host protease for HIV-1 gp160 processing in CD4+ T lymphocytes.

Authors:  L Miranda; J Wolf; S Pichuantes; R Duke; A Franzusoff
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

2.  The role of eukaryotic subtilisin-like endoproteases for the activation of human immunodeficiency virus glycoproteins in natural host cells.

Authors:  S Hallenberger; M Moulard; M Sordel; H D Klenk; W Garten
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

Review 3.  Antivirals targeting paramyxovirus membrane fusion.

Authors:  Erik M Contreras; Isaac Abrrey Monreal; Martin Ruvalcaba; Victoria Ortega; Hector C Aguilar
Journal:  Curr Opin Virol       Date:  2021-09-27       Impact factor: 7.090

4.  Involvement of the leader sequence in Sendai virus pathogenesis revealed by recovery of a pathogenic field isolate from cDNA.

Authors:  Yutaka Fujii; Takemasa Sakaguchi; Katsuhiro Kiyotani; Cheng Huang; Noriko Fukuhara; Yoshiko Egi; Tetsuya Yoshida
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

5.  Species based synonymous codon usage in fusion protein gene of Newcastle disease virus.

Authors:  Chandra Shekhar Kumar; Sachin Kumar
Journal:  PLoS One       Date:  2014-12-05       Impact factor: 3.240

6.  Paramyxovirus Glycoproteins and the Membrane Fusion Process.

Authors:  Hector C Aguilar; Bryce A Henderson; J Lizbeth Zamora; Gunner P Johnston
Journal:  Curr Clin Microbiol Rep       Date:  2016-07-05

7.  Nipah virus fusion protein: influence of cleavage site mutations on the cleavability by cathepsin L, trypsin and furin.

Authors:  Sandra Diederich; Erik Dietzel; Andrea Maisner
Journal:  Virus Res       Date:  2009-08-07       Impact factor: 3.303

Review 8.  Newcastle disease virus: current status and our understanding.

Authors:  Ketan Ganar; Moushumee Das; Sugandha Sinha; Sachin Kumar
Journal:  Virus Res       Date:  2014-03-01       Impact factor: 3.303

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.